Prostate cancer · 7 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Aspirin and Dexamethasone Variant #01 | — | R 2 430 | 28d | — | — | ~2 | ~R 4 861 indirect | — |
Cyclophosphamide monotherapy Variant #01 | — | R 1 680 | 28d | — | ~15.8 mo | ~1 | ~R 1 680 PFS proxy · indirect | 1 |
Vinblastine monotherapy Variant #01 | — | R 1 444 | 14d | — | — | ~2 | ~R 2 888 indirect | — |
Doxorubicin monotherapy Variant #01 | — | R 902 | 21d | ~6.0 mo | ~8.2 mo | ~9 | ~R 8 114 PFS proxy · indirect | 18 |
Cyclophosphamide, Prednisone, Diethylstilbestrol Variant #01 Partial | — | R 292 | 30d | — | — | ~2 | ~R 584 indirect | — |
Doxorubicin and Strontium-89 Variant #01 Partial | — | — | 42d | — | — | ~1 | — | — |
Placebo Partial | — | — | — | — | 21.7 mo | — | — | 10 |
7 of 7 regimens shown